Drug updated on 11/4/2024
| Dosage Form | Tablet (oral; 2.5 mg, 5 mg, 10 mg, 20 mg) |
| Drug Class | Beta-adrenergic receptor inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of hypertension, to lower blood pressure
- Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
Latest News
Summary
- This summary is based on the review of six systematic review(s)/meta-analysis(es). [1-6]
- Nebivolol significantly reduced both systolic (SBP) and diastolic blood pressure (DBP) compared to placebo but did not show significant differences in SBP or DBP reductions compared to other beta-blockers.
- Nebivolol improved lipid profile outcomes, showing significant decreases in LDL-C (low-density lipoprotein-cholesterol) and increases in HDL-C (high-density lipoprotein cholesterol) compared to other beta-blockers.
- In subgroup populations, nebivolol displayed variable pharmacokinetics, with poor metabolizers (PMs) and patients with chronic kidney disease (CKD) experiencing higher AUC levels, while obese patients showed increased drug clearance.
- Nebivolol was associated with a lower incidence of adverse events compared to other second-generation beta-blockers and maintained stable heart rate levels without significant reduction compared to other beta-blockers.
- Drug-drug interactions were observed with nebivolol, showing increased C(max), AUC(0-infinity), and half-life when co-administered with drugs such as bupropion, duloxetine, fluvoxamine, paroxetine, lansoprazole, and fluoxetine.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Bystolic (nebivolol) Prescribing Information. | 2024 | AbbVie Inc., North Chicago, IL |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| A Systematic Literature Review and Network Meta-analysis of Azilsartan Medoxomil Compared to Other Anti-hypertensives Efficacy in Lowering Blood Pressure Amongst Mild to Moderate Hypertensive Patients | 2024 | Advances In Therapy |
| Effects of Nebivolol therapy on hemodynamic parameters and lipid profile compared to other beta blockers in patients with essential hypertension: a systematic review and meta-analysis | 2024 | Caspian Journal Of Internal Medicine |
| Clinical pharmacokinetics of nebivolol: a systematic review | 2023 | Drug Metabolism Reviews |
| Effects of Major Antihypertensive Drug Classes on Erectile Function: a Network Meta-analysis | 2022 | Cardiovascular Drugs And Therapy |
| Efficacy and safety of nebivolol in hypertensive patients: a meta-analysis of randomized controlled trials | 2020 | The Journal Of International Medical Research |
| Effects of nebivolol versus other antihypertensive drugs on the endothelial dysfunction in patients with essential hypertension | 2020 | Bioscience Reports |